Also trades as: SLXN (NASDAQ) · $vol 1M
SLXNW NASDAQ
Silexion Therapeutics Ltd.
1W: -39.4%
1M: -47.4%
3M: -81.8%
YTD: -84.6%
1Y: -80.1%
$0.01
-0.00 (-21.05%)
Weekly Expected Move ±45.6%
$0
$0
$0
$0
$0
Overview
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Supply Chain
Income Trends
Revenue
$0
+0.0% ▲
Gross Profit
-$14K
+44.0% ▲
Operating Income
-$12M
+7.5% ▲
Net Income
-$12M
+27.6% ▲
EPS (Diluted)
$-8.96
-135.2% ▼
EBITDA
-$12M
+29.3% ▲
Profit Margins
Year-over-Year Growth
View Full Income Statement
| Line Item | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 |
| YoY Growth | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% |
| Cost of Revenue | $0 | $0 | $0 | $25K | $14K |
| Gross Profit | $0 | $0 | $0 | -$25K | -$14K |
| Gross Margin | — | — | — | — | — |
| R&D Expenses | $0 | $0 | $4M | $6M | $7M |
| SG&A Expenses | $944K | $1M | $928K | $7M | $4M |
| Operating Expenses | $944K | $1M | $5M | $13M | $12M |
| Operating Income | -$944K | -$1M | -$5M | -$13M | -$12M |
| Operating Margin | — | — | — | — | — |
| Interest Expense | $0 | $0 | $9K | $52K | $0 |
| Income Before Tax | -$755K | $584K | -$5M | -$17M | -$12M |
| Tax Expense | $0 | $0 | $32K | $10K | $3K |
| Net Income | -$755K | $584K | -$5M | -$16M | -$12M |
| Net Margin | — | — | — | — | — |
| EPS (Diluted) | $-0.46 | $0.35 | $0.39 | $25.49 | $-8.96 |
| EBITDA | -$755K | $584K | -$5M | -$16M | -$12M |
| Shares Outstanding | 2M | 2M | 681094 | 623846 | 1M |